Issue 1/2007
Content (17 Articles)
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer
Masahiro Tabata, Katsuyuki Kiura, Niro Okimoto, Yoshihiko Segawa, Tetsu Shinkai, Toshiro Yonei, Shoichi Kuyama, Shingo Harita, Katsuyuki Hotta, Hiroshi Ueoka, Mitsune Tanimoto
Effect of pH and human serum albumin on the cytotoxicity of a glucuronide prodrug of 9-aminocamptothecin
Zeljko M. Prijovich, Yu-Lin Leu, Steve R. Roffler
Urinary excretion of l-carnitine and its short-chain acetyl-l-carnitine in patients undergoing carboplatin treatment
Angelo Mancinelli, S. D’Iddio, R. Bisonni, F. Graziano, P. Lippe, M. Calvani
Class III β-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site
Pascal Sève, Tony Reiman, Raymond Lai, John Hanson, Cheryl Santos, Lorelei Johnson, Laith Dabbagh, Michael Sawyer, Charles Dumontet, John R. Mackey
Inhibition of NF-κB-mediated transcription and induction of apoptosis by melampolides and repandolides
Guoyi Ma, Shabana I. Khan, Gloria Benavides, Wolfgang Schühly, Nikolaus H. Fischer, Ikhlas A. Khan, David S. Pasco
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models
Li-mou Zheng, Zujin Li, Lanzhen Liu, Bai Louis Song, Ivan King
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study
Masahiro Tabata, Toshiyuki Kozuki, Hiroshi Ueoka, Katsuyuki Kiura, Shingo Harita, Atsuhiko Tada, Takuo Shibayama, Nagio Takigawa, Toshiro Yonei, Kenichi Gemba, Yoshihiko Segawa, Daizo Kishino, Shinya Tada, Shunkichi Hiraki, Mitsune Tanimoto
Phase II trial of 10-EDAM in the treatment of metastatic breast cancer
Garth A. Beinart, Ana M. Gonzalez-Angulo, Kristine Broglio, Debbie Frye, Ronald Walters, Frankie Ann Holmes, Shivaji Gunale, Daniel Booser, Julian Rosenthal, Kapil Dhingra, James A. Young, G. N. Hortobagyi
Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells
Chong-Zhi Wang, Xiaoji Luo, Bin Zhang, Wen-Xin Song, Ming Ni, Sangeeta Mehendale, Jing-Tian Xie, Han H. Aung, Tong-Chuan He, Chun-Su Yuan
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC)
Roger B. Cohen, Corey J. Langer, George Rajan Simon, Peter David Eisenberg, John Daniel Hainsworth, Stefan Madajewicz, Thomas Michael Cosgriff, Kristen Pierce, Huiping Xu, Katherine Liau, Diane Healey
Irinotecan–cisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line
Jason Zastre, Malathi Anantha, Euan Ramsay, Marcel Bally
The apoptotic effect of cordycepin on human OEC-M1 oral cancer cell line
Wei-Ciao Wu, Jenn-Ren Hsiao, Yu-Yan Lian, Chun-Yu Lin, Bu-Miin Huang
The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men
Martijn Triesscheijn, Marjan Ruevekamp, Ruud Out, Theo J. C. Van Berkel, Jan Schellens, Paul Baas, Fiona A. Stewart
Weekly administration of topotecan–paclitaxel as second-line treatment in ovarian cancer
G. P. Stathopoulos, N. A. Malamos, G. Aravantinos, S. Rigatos, Ch. Christodoulou, J. Stathopoulos, D. Skarlos
Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study
Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Yoon Young Cho, Deok Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim, Ho Jin Shin, Joo Seop Chung, Goon Jae Cho, Won-Sik Lee, Young-Don Joo, Chang-Hak Sohn, Suk Joong Oh
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma
Monika K. Krzyzanowska, Ian F. Tannock, Gina Lockwood, Jennifer Knox, Malcolm Moore, Georg A. Bjarnason
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial
D. Binder, H. Schweisfurth, C. Grah, C. Schäper, B. Temmesfeld-Wollbrück, G. Siebert, N. Suttorp, T. Beinert